PRELIMINARY PROGRAM

More documents

Recommendations

Info

CME Information CME Accreditation and Designation The China Interventional Therapeutics is accredited by the Accreditation Council for Continuing Medical Education of Ministry of Health of China to provide continuing medical education for physicians. This education activity has been designated for 8 national category-1 CME Credits in China. Six hours of physician participation in CIT equals 1 credit. Documentation of awarded credit is provided for registered attendees in exchange for completed activity evaluations. Certificates of attendance are provided to all registered attendees. The following activities are not included in the official CIT CME program: luncheon workshops, evening symposia and interventional vascular simulation sessions. Learning Objectives By the end of the congress, participants should be able to Relate the results from important clinical trials and evidencebased medicine that guide the management of patients with atherosclerosis and structural heart disease Integrate new interventional techniques and procedures to the care of patients with complex coronary artery disease, peripheral vascular disease, structural heart disease, and heart rhythm Integrate appropriate pharmacological management in the care of patients undergoing diagnostic angiography and interventional therapies before, during, and after catheterization Distinguish between new interventional technologies and propose their appropriate applications to patients with cardiovascular disease Target Audience This congress is designed for interventional cardiologists, radiologists, clinical cardiologists, basic scientists, vascular medicine specialists, surgeons, and other health care professionals with a special interest in the field of interventional vascular therapy and medicine. Activity Evaluation Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs. Disclosure Statement It is the policy of the Chinese Medical Association to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational programs. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity. Discussion of off-label product usage, and/or off-label product use during live cases, is made at the sole discretion of the faculty. Off-label product discussion and/or off-label product use is not endorsed by the Chinese Medical Association or the course directors for this activity. Faculty participating in continuing medical education activities sponsored by the Chinese Medical Association are required to disclose to the program audience any real or apparent conflict of interest related to the content of their presentation(s). Faculty not complying with this policy are not permitted to participate in this activity. Program Sponsorship and Support The congress is sponsored by Chinese Medical Association, CIT Board of Directors, Chinese Society of Cardiology, and Cardiovascular Research Foundation / Transcatheter Cardiovascular Therapeutics (TCT), and partially funded through educational grants from commercial supporters. The CIT strives to ensure that its programs are as educational as possible and free from bias. To support this endeavor, CIT director and co-directors create organizing and scientific committees to assist in educational content development and content oversight for live cases, concurrent sessions, case reviews, workshops, and scientific symposia. These sessions are developed without influence from commercial supporters. 08
Hot Topics Opening and Plenary Topics Celebrating the 10 th Anniversary: The Journey of Percutaneous Cardiovascular Interventions in China Stable Ischemic Heart Disease: What's Role for Revascularization The Asia Pacific Region: An Emerging Center of Growth and Worldwide Leadership in Interventional Cardiovascular Therapeutics! Acute MI: State of the Art DAPT Issues: Duration and Dilemmas after PCI Complex PCI: CTOs, Bifurcations, and MVD Future Visions: What's Next Future of Interventional Cardiology Renal Denervation for Treatment of Hypertension The Future of Coronary Intervention Is Fully Bioresorbable Vascular Scaffolds Oxygen Therapy in STEMI New Insights into Vulnerable Plaque Detection Treatment of Vulnerable Plaque with DEB New Direction of CTO Wire Development New Device for Retrograde Approach to CTOs Transcatheter Valve Therapy Transcatheter AVI: Partner Perspectives Multidisciplinary Approach to Interventional Therapy of Aortic Stenosis Valve Team Concept Prevention and Treatment of Vascular Complications during TAVI Stroke Protection during TAVI Gender Differences in Patients Undergoing Percutaneous Replacement of Aortic Valve Transcatheter Valve in Valve Implantation for Failed Surgical Valves Novel TAVI Devices Percutaneous Mitral Valve Repair: Update on the Clinical Data and Global Experience with the MitraClip Device The Insufficiency of Transcatheter Mitral Valve Therapy Transcatheter Pulmonary Valve Implantation with Melody and Sapien-Edwards Valves Coronary Revascularization Strategy Ischemia as a Target for Therapeutic Intervention in CAD and Its Pathophysiologic Underpinnings PCI vs. CABG in Left Main Disease: A Meta-Analysis of Randomized Clinical Trials Treating Complex Patients/Lesions: Lessons from SYNTAX Functional SYNTAX Score Guidance for PCI in Multivessel Disease Patients Integrating the SYNTAX Score into Practice: Utility, Pitfalls, and New Directions Impact of Target Vessel Revascularization and Stent Thrombosis on Patients Undergoing Percutaneous Coronary Intervention Impact of DAPT Interruption on Stent Thrombosis and MACE Measuring Biomarkers after PCI: Routinely, Ad Hoc, or Not at All Patient Selection for PCI with Low EF Drug-Eluting Stent Platelet Hyporesponsiveness and Stent Thrombosis Insights from ADAPT-DES The 3rd Generation DES: When Is a Change a Change Stent Thrombosis: Is It an Important Issue in 2012 Absorb Physiology Trial Randomized Comparison of Cost Saving and Effectiveness of Oral Rapamycin plus BMS with DES Drug-Eluting Balloon Technology: Development and Clinical Update Drug-Eluting Balloon Prior to BMS Stenting: Insights from the PIONEER Trial Safety of Everolimus-Eluting Stents Compared to Other DES: Comprehensive Meta-Analysis Biofreedom Stent EVOLVE Study Results Management of DES In-Stent Restenosis Female Outcomes with DES 09
Page 1 and 2: CHINA INTERVENTIONAL THERAPEUTICS I
Page 3 and 4: CIT Course Directors & Organizers H
Page 5 and 6: CIT2012 Preliminary Program Associa
Page 7: Welcome Message Dear Colleagues and
Page 11 and 12: Program at a Glance 07:00PM Functio
Page 13 and 14: Opening of CIT 2012 and Plenary Ses
Page 15 and 16: Call for Abstracts The CIT invites
Page 17 and 18: CIT Theme Issue of Chinese Medical
Page 19 and 20: Registration Information Official C
Page 21 and 22: Congress Hotels InterContinental Be
Page 23 and 24: Housing Form, CIT2012 Reservation D

PRELIMINARY PROGRAM

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?